

RECORDATI: PUBLIC DISCLOSURE COMPLIANCE

Milan, 6 February 2019 – Please be informed that the summary report of the voting results related to the resolutions approved by the Shareholders' Meeting on 5 February 2019, pursuant to article 125-quarter of the Legislative Decree 58/98, is available to the public on the Company's website (www.recordati.it; Investors Area, Shareholders' Meetings Section) and on the "1info" storage mechanism (www.1info.it).

Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,100, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations throughout the whole of Europe, including Russia, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2017 was € 1,288.1 million, operating income was € 406.5 million and net income was € 288.8 million.

For further information:

Recordati website: www.recordati.com

Investor Relations

Marianne Tatschke

(39)0248787393

e-mail: investorelations@recordati.it

Media Relations

Studio Noris Morano

(39)0276004736, (39)0276004745

e-mail: norismorano@studionorismorano.com